Catalyst Pharmaceuticals to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
Catalyst Pharmaceuticals, Inc. (Nasdaq: CPRX) announced that Patrick J. McEnany, Chairman and CEO, and the management team will attend the H.C. Wainwright 24th Annual Global Investment Conference from September 12-14, 2022. An on-demand presentation will be accessible to registered attendees on September 12 at 7:00 AM Eastern Time via the conference portal. Additionally, the presentation will be available on Catalyst's website. The company specializes in developing novel medicines for rare diseases, notably with FDA-approved FIRDAPSE® for Lambert-Eaton myasthenic syndrome.
- None.
- None.
CORAL GABLES, Fla., Sept. 09, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today announced that Patrick J. McEnany, Chairman and CEO of Catalyst, along with other members of the management team, will participate in the hybrid in-person and virtual H.C. Wainwright 24th Annual Global Investment Conference being held on September 12-14, 2022.
The Company’s on-demand presentation will be available to registered attendees through the H.C. Wainwright conference portal beginning Monday, September 12, 2022, at 7:00 AM Eastern Time. A copy of the presentation will be available on the Investor Relations section of the Company’s website at www.catalystpharma.com. Catalyst’s management team will participate in one-on-one meetings during the scheduled virtual meeting times.
About Catalyst Pharmaceuticals
Catalyst Pharmaceuticals is a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases. With exceptional patient focus, Catalyst is committed to developing a robust pipeline of cutting-edge, best-in-class medicines for rare diseases. Catalyst's New Drug Application for FIRDAPSE® (amifampridine) Tablets 10 mg for the treatment of adults with Lambert-Eaton myasthenic syndrome ("LEMS") was approved in 2018 by the U.S. Food & Drug Administration ("FDA"), and FIRDAPSE is commercially available in the United States as a treatment for adults with LEMS. Further, Canada's national healthcare regulatory agency, Health Canada, has approved the use of FIRDAPSE for the treatment of adult patients in Canada with LEMS.
For additional information about the Company, please visit www.catalystpharma.com.
Forward-Looking Statements
This press release contains forward-looking statements. Forward-looking statements involve known and unknown risks and uncertainties, which may cause Catalyst's actual results in future periods to differ materially from forecasted results. A number of factors, including those factors described in Catalyst's Annual Report on Form 10-K for the fiscal year 2021 and its other filings with the U.S. Securities and Exchange Commission ("SEC"), could adversely affect Catalyst. Copies of Catalyst's filings with the SEC are available from the SEC, may be found on Catalyst's website, or may be obtained upon request from Catalyst. Catalyst does not undertake any obligation to update the information contained herein, which speaks only as of this date.
Source: Catalyst Pharmaceuticals
FAQ
What is Catalyst Pharmaceuticals announcing on September 9, 2022?
Who will represent Catalyst Pharmaceuticals at the H.C. Wainwright conference?
When will the on-demand presentation by Catalyst Pharmaceuticals be available?
Where can I find the presentation from Catalyst Pharmaceuticals?
What is FIRDAPSE and its significance to Catalyst Pharmaceuticals?
